Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 10/20 | 0.75 |
| ▸ | ELOC | Q15369 | 2/20 | 0.75 |
| ▸ | ELOB | Q15370 | 2/20 | 0.75 |
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | BRD4 | O60885 | 3/20 | 0.61 |
| ▸ | NAMPT | P43490 | 5/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186168 | 1.00 | VHL (0.75) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22325241 | 1.00 | VHL (0.75) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22186170 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22186167 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL29290867 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL24201263 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL24201266 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL21308313 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22325294 | 0.99 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL24201281 | 0.97 | VHL (0.70) | VHLELOCELOBEGFRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3618833-B1 | TRIPARTITE ANDROGEN RECEPTOR ELIMINATORS, METHODS AND USES THEREOF | SPG THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3920923-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | University of Florida Research Foundation, Incorporated (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113660937-A | Therapeutic agents and methods of treatment | 佛罗里达大学研究基金公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210283261-A1 | Compositions and Methods for Treating ALK-Mediated Cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-09-16 | — | — | US | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169628-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | HDGF, NFATC1, HGF | VHL 224/4885ELOC 2243/4885ELOB 388/4885 |
| US-20210283261-A1 | Compositions and Methods for Treating ALK-Mediated Cancer | ALK, BCR, TP53 | VHL 164/4885ELOC 460/4885ELOB 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.